Alnylam RNAi Leader to Present at Canaccord Growth Conference

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

08/05/2025 - 08:00 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45^th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET.

A live audio webcast of the presentation will be available on the Investors section of the Company鈥檚 website, . A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam鈥檚 commercial RNAi therapeutic products include AMVUTTRA^庐 (vutrisiran), ONPATTRO^庐 (patisiran), GIVLAARI^庐 (givosiran), and OXLUMO^庐 (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio^庐 (inclisiran) and Qfitlia^鈩� (fitusiran), which are being developed and commercialized by Alnylam鈥檚 partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its 鈥�Alnylam P⁵x25鈥� strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @, or on , , or .